102 related articles for article (PubMed ID: 20658743)
1. Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer.
Bilgi O; Karagoz B; Alacacioglu A; Ozgun A; Tuncel T; Gokhan-Kandemir E
J BUON; 2010; 15(2):395. PubMed ID: 20658743
[No Abstract] [Full Text] [Related]
2. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Shao N; Jin S; Zhu W
J Thorac Oncol; 2012 Feb; 7(2):470-2. PubMed ID: 22252565
[No Abstract] [Full Text] [Related]
3. Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Guo S; Liang Y; Zhou Q
J Thorac Oncol; 2011 Feb; 6(2):406-8; author reply 408. PubMed ID: 21252725
[No Abstract] [Full Text] [Related]
4. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
[TBL] [Abstract][Full Text] [Related]
5. [Recent progress in the treatment of ED small cell lung cancer].
Nokihara H; Ohe Y
Nihon Rinsho; 2002 May; 60 Suppl 5():480-4. PubMed ID: 12101718
[No Abstract] [Full Text] [Related]
6. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Jiang L; Yang KH; Guan QL; Mi DH; Wang J
Intern Med J; 2012 Dec; 42(12):1297-309. PubMed ID: 22530708
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
8. Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer.
Lindgren D; Cadman E; Erichson R; Grann V; Sachs K
Cancer Treat Rep; 1984 Sep; 68(9):1159-61. PubMed ID: 6090015
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
[TBL] [Abstract][Full Text] [Related]
10. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Yashiki C; Hirose T; Okuda K; Yamaoka T; Ohnishi T; Adachi M; Nakamura A
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1839-43. PubMed ID: 19920385
[TBL] [Abstract][Full Text] [Related]
12. Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.
Lebeau B; Baud M; Masanes MJ; Febvre M; Mokhtari T; Chouaïd C
Chemotherapy; 2011; 57(3):253-8. PubMed ID: 21654168
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
[TBL] [Abstract][Full Text] [Related]
14. [Irinotecan].
Yokoyama A
Nihon Rinsho; 2002 May; 60 Suppl 5():339-42. PubMed ID: 12101684
[No Abstract] [Full Text] [Related]
15. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
Agatsuma T; Koizumi T; Kanda S; Ito M; Urushihata K; Yamamoto H; Hanaoka M; Kubo K
J Thorac Oncol; 2011 Dec; 6(12):2130-4. PubMed ID: 21892103
[TBL] [Abstract][Full Text] [Related]
17. Small cell lung cancer and chemotherapy.
Nardini S
Monaldi Arch Chest Dis; 1994 Apr; 49(2):178-9. PubMed ID: 8049707
[No Abstract] [Full Text] [Related]
18. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
Littlewood TJ; Smith AP; Anderson G; Chappell AG; James KW
Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
